Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.52 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL16874119 | 0.85 | CHRNA7 (0.52) | CHRNA7MAPTTRAP1 | |
| Bromide SCHEMBL16874120 | 0.85 | CHRNA7 (0.52) | CHRNA7MAPTTRAP1 | |
| Bromide SCHEMBL28435573 | 0.79 | CHRNA7 (0.72) | CHRNA7MAPTPSMB5 | |
| Bromide SCHEMBL28895881 | 0.76 | ALDH1A1 (0.57) | CHRNA7MAPT | |
| SCHEMBL2558549 | 0.76 | ALB (0.57) | TRIM24TYRTRIM33POLBMAPT | |
| SCHEMBL20339391 | 0.76 | TYR (0.63) | TRIM24TYRTRIM33POLBMAPT | |
| SCHEMBL16873694 | 0.76 | TYR (0.54) | TRIM24TYRTRIM33POLBMAPT | |
| SCHEMBL7323609 | 0.76 | TRIM24 (0.58) | TRIM24TYRTRIM33POLBMAPT | |
| SCHEMBL4556765 | 0.75 | TYR (0.62) | TRIM24TYRTRIM33POLBMAPT | |
| SCHEMBL3195593 | 0.75 | TYR (0.57) | TRIM24TYRTRIM33POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230098649-A1 | MITOCHONDRIA-TARGETED ISOKETAL/ISOLEVUGLANDIN SCAVENGERS AND USES THEREOF | VANDERBILT UNIVERSITY | 2023-03-30 | — | — | US | disclosed |
| EP-4097115-A1 | MITOCHONDRIA-TARGETED ISOKETAL/ISOLEVUGLANDIN SCAVENGERS AND USES THEREOF | Vanderbilt University (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021154877-A1 | MITOCHONDRIA-TARGETED ISOKETAL/ISOLEVUGLANDIN SCAVENGERS AND USES THEREOF | VANDERBILT UNIVERSITY (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230098649-A1 | MITOCHONDRIA-TARGETED ISOKETAL/ISOLEVUGLANDIN SCAVENGERS AND USES THEREOF | NLN, SHMT2, HOGA1 | CHRNA7 3772/4885TRIM24 1014/4885TYR 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.